> Research summary—not medical advice. This page synthesizes published research on a mechanism-level intervention. It is not a clinical recommendation.
Consult a qualified healthcare provider before making any changes to diet, supplementation, or treatment.
Contents
1. Overview2. Mechanism of Action3. Dosage and Administration4. Monitoring5. Contraindications and Risks6. ConnectionsOverview#
The ketogenic diet restricts carbohydrates to 20-50 g/day (or <10% of calories), forcing a metabolic shift from glucose oxidation to fatty acid beta-oxidation and hepatic ketogenesis.
The resulting ketone bodies—beta-hydroxybutyrate (BHB), acetoacetate, and acetone—serve as alternative fuel and as signaling molecules with distinct anti-inflammatory and epigenetic effects.
> Clinical disclaimer: The ketogenic diet requires medical supervision, especially in patients on diabetes medications (hypoglycemia risk), anticonvulsants (dose adjustments needed), or with kidney disease. Nutritional adequacy must be monitored. Not appropriate for patients with fatty acid oxidation disorders, porphyria, or pyruvate carboxylase deficiency.
Mechanism of Action#
The ketogenic diet operates through metabolic reprogramming with downstream effects on inflammation, gene expression, and the microbiome.
BHB as HDAC inhibitor: Beta-hydroxybutyrate directly inhibits Class I and IIa histone deacetylases, promoting expression of anti-oxidant genes (FOXO3a, SOD2, catalase) and neurotrophic factors (BDNF). This epigenetic mechanism distinguishes the ketogenic diet from simple caloric restriction.
Insulin reduction: Carbohydrate restriction profoundly lowers circulating insulin—the most direct dietary manipulation of insulin signaling. Relevant for Polycystic Ovary Syndrome, Type 2 Diabetes, and insulin-driven cancer metabolism.
Microbiome remodeling: The ketogenic diet produces a distinctive microbiome shift—increased Akkermansia muciniphila and Parabacteroides merdae, which cross-feed to elevate hippocampal GABA/glutamate ratio. In MS, Swidsinski showed normalized colonic bacterial mass, suggesting architectural rather than just compositional changes.
Mitochondrial bypass: Ketones enter the electron transport chain at complex II, bypassing the complex I defect central to Parkinson's Disease and other mitochondrial disorders.
Anti-inflammatory signaling: BHB blocks NLRP3 inflammasome activation and reduces IL-1-beta, TNF-alpha, and IL-6 production.
Dosage and Administration#
| Parameter | Standard Protocol | Notes |
|---|---|---|
| Carbohydrate | 20-50 g/day (5-10% calories) | Strict <20 g for epilepsy; 30-50 g tolerated for other conditions |
| Fat | 70-80% of calories | Emphasize EVOO, avocado, fatty fish, nuts; limit saturated fat |
| Protein | 15-20% of calories | Moderate—excess protein converts to glucose via gluconeogenesis |
| Induction period | 2-4 weeks to achieve stable ketosis | "Keto flu" (fatigue, headache) common during adaptation |
| Duration | Condition-dependent: 3-6 months minimum for assessment | Epilepsy: often long-term. PCOS/MS: 3-6 month trial |
| Modified versions | MCT ketogenic, modified Atkins, low glycemic index treatment | Lower fat ratio improves adherence with similar ketosis in some patients |
Monitoring#
Blood ketone levels (BHB): Target 0.5-3.0 mmol/L for nutritional ketosis. Urine ketone strips are unreliable after adaptation. Blood BHB meters preferred.
Lipid panel: At baseline, 3 months, 6 months. LDL may transiently rise; monitor LDL particle size (large buoyant = less concerning than small dense).
Renal function: BUN/creatinine at baseline and 3 months. Adequate hydration essential. Electrolytes: Sodium, potassium, magnesium—ketosis increases urinary electrolyte loss.
Supplementation often needed (sodium 3-5g, potassium 1-3g, magnesium 300-500mg daily). Bone density: Long-term pediatric KD associated with reduced bone mineral density. Monitor in children and postmenopausal women.
Contraindications and Risks#
Fatty acid oxidation disorders: Absolute contraindication—inability to utilize fat for energy makes KD lethal. Porphyria, pyruvate carboxylase deficiency: Absolute contraindications. Kidney stones: 3-7% incidence in long-term KD (especially pediatric).
Potassium citrate prophylaxis recommended.
Hypoglycemia: Patients on insulin or sulfonylureas require medication dose reduction BEFORE starting KD. Nutrient deficiencies: Fiber, B vitamins, vitamin C, and minerals may be insufficient without careful planning. Micronutrient supplementation recommended.
Adherence: 30-50% dropout rate in clinical trials. Social and practical difficulties limit long-term sustainability.
LDL cholesterol: Lean-mass hyper-responders may see dramatic LDL increases. Individual cardiovascular risk assessment needed.
Connections#
Entities: beta-hydroxybutyrate, Akkermansia muciniphila, insulin
Concepts: HDAC-inhibition, Mitochondrial Dysfunction, Short-Chain Fatty Acids (SCFAs), Gut-Brain Axis, nutritional-ketosis
Related interventions: Mediterranean Diet (alternative anti-inflammatory diet), Vitamin D Supplementation (synergistic immune modulation in MS)
Related pages: ketogenic diet ms (MS-specific deep dive)
Signatures: Multiple Sclerosis, Epilepsy, Polycystic Ovary Syndrome, Parkinson's Disease, Autism Spectrum Disorder
> Educational content, not medical advice. This page describes mechanisms by which the intervention interacts with the microbiome and metal ecology. It is not a treatment recommendation.
Clinical decisions about any intervention should be made with a qualified healthcare practitioner who knows your individual history.
Article network
Mentioned here 13
Pages linking here 7
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers
WikiBiome Deploy Bot · +33 −33
Inspect exact Git diff ↗ - published revision
ingest: 87 papers (17 endometriosis, 67 erectile dysfunction, 3 cross-condition)
WikiBiome Deploy Bot · +1 −1
Inspect exact Git diff ↗ - published revision
pre-overnight checkpoint 2026-04-18
WikiBiome Deploy Bot · +2 −2
Inspect exact Git diff ↗ - published revision
Adversarial audit fixes: confidence downgrades, disclaimers, STOP safety, entity cleanup
WikiBiome Deploy Bot · +8 −1
Inspect exact Git diff ↗ - published revision
v2 migration Priority 4: 13 interventions + 14 STOPs upgraded with cureva_status, karen_brain_primitives, evidence_level
WikiBiome Deploy Bot · +17 −0
Inspect exact Git diff ↗ - published revision
WikiBiome v2 migration: signature pages + safety fixes + gap analysis
WikiBiome Deploy Bot · +125 −0
Inspect exact Git diff ↗